28,794 Shares in argenx SE (NASDAQ:ARGX) Acquired by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. bought a new stake in argenx SE (NASDAQ:ARGX - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 28,794 shares of the company's stock, valued at approximately $15,609,000.

Other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. lifted its position in argenx by 620.0% during the second quarter. Blue Trust Inc. now owns 72 shares of the company's stock valued at $28,000 after buying an additional 62 shares during the period. J.Safra Asset Management Corp increased its stake in shares of argenx by 590.0% in the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company's stock worth $30,000 after acquiring an additional 59 shares in the last quarter. GAMMA Investing LLC boosted its stake in argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company's stock worth $51,000 after acquiring an additional 40 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in argenx in the second quarter worth about $76,000. Finally, Toronto Dominion Bank increased its stake in shares of argenx by 16.5% during the first quarter. Toronto Dominion Bank now owns 303 shares of the company's stock valued at $119,000 after purchasing an additional 43 shares in the last quarter. 60.32% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Guggenheim reissued a "buy" rating and issued a $585.00 price target on shares of argenx in a research report on Thursday, September 26th. Wedbush raised their price target on argenx from $519.00 to $560.00 and gave the company an "outperform" rating in a report on Friday, July 26th. Truist Financial lifted their price target on argenx from $480.00 to $540.00 and gave the stock a "buy" rating in a research report on Monday, July 22nd. HC Wainwright increased their price objective on shares of argenx from $504.00 to $533.00 and gave the company a "buy" rating in a research report on Friday, July 26th. Finally, Deutsche Bank Aktiengesellschaft cut shares of argenx from a "buy" rating to a "hold" rating in a report on Friday, October 4th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, argenx currently has an average rating of "Moderate Buy" and an average price target of $550.44.

argenx Stock Performance

Shares of NASDAQ ARGX traded up $5.68 during midday trading on Friday, hitting $556.83. 135,027 shares of the company's stock traded hands, compared to its average volume of 307,768. The stock has a market capitalization of $33.09 billion, a price-to-earnings ratio of -98.38 and a beta of 0.63. The firm has a fifty day moving average of $534.84 and a 200 day moving average of $460.35. argenx SE has a 1 year low of $327.73 and a 1 year high of $571.97.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of ($0.89) by $1.34. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. The business had revenue of $489.43 million for the quarter, compared to the consensus estimate of $436.66 million. During the same period last year, the firm earned ($1.69) earnings per share. On average, equities analysts anticipate that argenx SE will post -0.37 earnings per share for the current year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.